Editor’s Note, October 24, 2013
Dear Subscriber, In the coming weeks we will be providing short profiles of selected companies presenting at the 7th Annual […]
Read more »
ISTO’s Cell Therapies Can Revolutionize Treatment of Joint, Bone Injuries
ISTO Technologies, Inc.is both a regenerative medicine and orthopedics company developing innovative cartilage and bone regeneration products for spinal therapy, sports medicine and trauma. ISTO is currently focused on the development of cell-based cartilage platform technology that can be applied to repair and regenerate damaged cartilage in the knee and spinal disc.
Read more »
Aridis Pharmaceuticals: Better Alternative to Traditional Antibiotics?
Aridis Pharmaceuticals is a private biotechnology company focusing on improved alternatives to traditional antibiotics for the treatment of pneumonia and Cystic Fibrosis in addition to a few other conditions.
Read more »“Regulatory Rush”-The SEC Lifts The Ban On General Solicitation
On July 10th, 2013 new changes to regulations regarding the general solicitation of securities was announced by the Securities and […]
Read more »
OneMedForum Recap: Del Mar Pharmaceuticals
Delmar Pharmaceuticals (DMPI) is a clinical and early stage Oncologyl Company focused on developing and commercializing leading anti-cancer therapies in high impact orphan oncological indications specifically where patients have failed contemporary therapy.
Read more »
OneMedForum Recap: Pressure Biosciences
Pressure Biosciences (PBIO) is a life sciences company centered on developing and commercializing a novel technology titled Pressure Cycling Technology (PCT).
Read more »
The Fly on the Wall: Athersys Publishes Study on Increasing Survival of Organ Transplants With Stem Cells
Athersys (ATHX) is a clinical stage based biopharmaceutical company with an exponentially growing pipeline and an array of products in therapeutics to treat significant and life-threatening diseases.
Read more »
PR Newswire: BioDelivery Sciences International Secures $20 Million in Debt Financing
A company to keep a look out for in the upcoming future is BioDelivery Sciences International (BDSI), a specialty pharmaceutical company with a platform of drug delivery technologies to develop, commercialize, and improve already proven applications of therapeutics.
Read more »
Global News Wire: Pluristem Therapeutics Forms Strategic Alliance with ChaBio & Diostech
Pluristem Therapeutics (PSTI) is a developer of placenta-based cell therapies. They have just formed a strategic alliance with Cha Bio&Diostech.
Read more »